Clinical analysis of autologous peripheral blood mononuclear cells for treating critical limb ischemia

Zhengdong Fang,Xiaotian Wang,Hejie Hu,Xiaojie Sun,Xinbao Ge,Can Cheng
DOI: https://doi.org/10.3969/J.issn.1672-6790.2017.04.003
2017-01-01
Abstract:Objective To evaluate long-term clinical outcomes after autologous peripheral blood mononuclear cells(PBMNC) implantation in patients with critical limb ischemia(CLI).Methods The clinical data of 72 patients with CLI were analyzed retrospectively.There were 29 patients with arteriosclerosis(ASO) and 43 patients with thromboangiitis obliterans(TAO).A series of clinical outcomes and laboratory findings were compared between the ASO and TAO group.Results In patients with ASO,clinical symptoms,ankle brachial pressure index (ABI)and transcutaneous oxygen pressure(TcpO2) improved after 1 month,but gradually decreased during 3-year follow-up and returned to baseline levels.In TAO group,clinical symptoms,ABI and TcpO2 were significantly increased after 1 month and remained high during 3-year follow-up.The amputation-free rates after PBMNC implantation were 17.2% in ASO group and 61.5% in TAO group.Conclusions PBMNC implantation is safe and effective in patients with CLI.Compared with ASO,PBMNC implantation is more effective in CLI patients with TAO disease.
What problem does this paper attempt to address?